The purpose of this review is to highlight major advances in the development and use of animal models for HIV-1 research during the last year.
INTRODUCTION
As we enter the third decade of research, the field remains constrained by the absence of animal models that fully recapitulate all aspects of infection and pathogenesis of HIV in humans. Despite this limitation, existing models provide valuable insights that complement findings from clinical studies. We have highlighted many of the major developments during the past year that have contributed to a better understanding of the limitations, or a further advancement of the animal models currently in use for HIV research. To summarize, we have briefly outlined some examples of the major contributions these models have made to understanding mechanisms of pathogenesis and in identifying and testing strategies to prevent infection and ameliorate disease pathogenesis.
MODEL REFINEMENTS AND USE OF ANIMAL MODELS TO ILLUMINATE MECHANISMS OF INFECTION AND PATHOGENESIS
Models that utilize simian immunodeficiency virus (SIV) infection of rhesus macaques continue to hold prominence in the literature. Several studies provided new insights on the development or avoidance of pathogenic consequences in SIV-infected macaques.
In the first of these, Chahroudi et al. [1] showed that the rates of mother-to-infant transmission in nonpathogenic versus pathogenic models for SIV may depend on an evolutionary adaptation to reduce the CD4 þ T-cell population in infants. In an excellent and timely review, this group recapitulates three key aspects of natural nonhuman primate (NHP) lentiviral infection that should provide a focus for future research to gain a complete understanding of the mechanisms of protection in natural SIV hosts [2] . Salgado et al. used humanized mice to explore the question of HIV control in elite suppressors. They isolated virus from elite suppressors and HIV-1infected patients, who have the usual progressive disease course, and compared how well the isolates from the two groups of patients replicated in culture and in humanized mice [3] . Their findings support the concept that elite suppressors possess unique host factors and are not typically infected with defective virus.
An investigation of the role of inflammation in HIV infection, in particular the impact of type I interferons, was conducted by Sandler et al. in SIVinfected rhesus macaques. They found that the timing of interferon-induced innate responses in acute SIV infection significantly affects overall disease course outweighing any detrimental consequences of increased immune activation caused by increasing the numbers of target cells [4] . Another group studying the differences in pathogenic versus nonpathogenic models of infection characterized a recently identified subset of memory T cells with stem cell-like properties, T(SCM), in rhesus macaques and in sooty mangabeys [5] . They concluded that increased proliferation and infection of CD4 þ T(SCM) may contribute to the pathogenesis of SIV infection in rhesus macaques. The dynamics of germinal center formation in lymphoid tissues following acute SIV infection was found to be an important predictor of disease in rhesus macaques. Hong et al. [6] showed that local production of interleukin-21 in lymphoid tissue germinal centers was an indicator of better control of viral replication and slower disease progression. Thus, limiting dysregulated lymphoid function may be a critical target for new therapeutics. Roederer et al.
identified one strategy by which both SIV and HIV escape host immune pressures. They found a twoamino-acid signature that alters antigenicity and confers neutralization resistance. This discovery, revealing selective pressure against neutralization-sensitive envelope glycoproteins (Envs), implies a shared mechanism of immune escape by SIV and HIV against a protective antibody response.
REPEATED TITERED VIRAL EXPOSURE DOES NOT PRIME MACAQUES
In a retrospective study involving cohorts of male Indian rhesus (n ¼ 40) and female pigtail (n ¼ 46) showed that infections in these models occur independently of exposure history. Using SHIV SF162P3 , this data provide assurance that neither inoculation route nor number of exposures required for infection correlates with postinfection viremia and support the concept that vaginal and rectal repeated low-dose exposure models in macaques provide a reasonable surrogate system for mucosal exposure with HIV-1. ]. The study provides detailed descriptions of early infection events in the FRT with critical insights for the role of mucus as an impediment to virus motility, and extrapolates the number of penetrating virions per coital act based on the highest levels of acute and chronic levels of infection. This work will augment and guide the development of new prevention strategies for women.
RELEVANCE OF CELL-ASSOCIATED VIRUS TRANSMISSION

NEW DISCOVERIES FOR SHIV/MACAQUE MODELS
Preclinical models of HIV-1 infection are critical to achieving a successful vaccine or development of effective immunotherapy strategies. SHIV infection of macaques has been the primary platform to model HIV-1 transmission and pathogenesis in humans, and the models are commonly used to evaluate protection efficacy of broadly neutralizing human monoclonal antibodies (bNmAbs) in the context of mucosal transmission and CCR5-using viruses. However, SHIVs have been criticized for lack
KEY POINTS
Both macaque and murine animal models continue to be refined and will add to our understanding of immune control of HIV.
Powerful human neutralizing mAbs are very effective in blocking infection and potentially in controlling postacute viremia.
SHIV isolates based on transmitted/founder HIV-1 isolate Envs are now available for testing.
Reduction of viral reservoirs in established infection may be a tractable approach with powerful antibodies or effector T cells.
of sustained robust viremia and variable CD4 þ T-cell loss in adult macaques. The most clinically relevant HIV-1 envelopes may be transmitted/founder (T/F) variants that are established upon mucosal exposure during human sexual transmission, but the most commonly used CCR5 SHIVs were isolated during chronic stages of HIV-1 infection after extended exposure to host immune pressures. Moreover, most SHIVs have been generated by amplification in cell culture followed by serial passage in macaques resulting in divergent SHIV envelopes with sequence variations not representative of most circulating HIV-1 isolates responsible for mucosal transmission in humans. ]. The SHIVs are mucosally transmitted and were neutralized by soluble CD4 and several HIV-1 broadly neutralizing antibodies (bNAbs). Together, these new approaches of SHIV development provide additional improvements to the SHIV/macaque models of HIV-1 infection.
The advancement of NHP models for HIV-1 infection and pathogenesis has been deterred by the lack of sustained replication of most SHIVs, especially those bearing recently transmitted Envs. Several host restriction factors are known to prevent robust replication. In an earlier study [13] , a macaque species-specific amino acid difference in the macaque CD4 receptor was identified that causes a reduction in infectivity of HIV in rhesus or pig-tailed macaques compared with the human CD4 receptor. Now, a new study [14 && ] has identified two substitutions in HIV-1 Env that enhance entry using the macaque CD4 receptor, A204E and G312V. However, these mutations resulted in conformational changes that expose variable domain epitopes and disrupt quaternary epitopes in the native Env trimer. These revelations sound a cautionary note for the use of SHIVs in vaccine and antibody testing, if the altered Envs are not representative of more native closed structures. More work is needed to determine how these findings affect our interpretation and future experimental design of SHIV challenge studies.
ANTIBODY-MEDIATED EFFECTOR FUNCTIONS IN HIV PREVENTION AND PATHOGENESIS
The degree to which antibody mediates Fc receptor antiviral functions may contribute to protection remains an open topic of debate and this has been recently reexamined in detail in excellent reviews [15] [16] [17] . Also, the role of anti-HIV antibody-dependent cellular cytotoxicity (ADCC) antibodies in the prevention and control of HIV infection has still not yet been fully determined. The RV144 HIV-1 vaccine trial induced anti-HIV ADCC antibodies that may have played a role in the partial protection observed encouraging continued efforts to show similar efficacy in the macaque model. Although passive transfer studies in macaques support a role for the Fc region of antibodies in assisting in the prevention of SHIV infection [18] , a study this year using passively transferred polyclonal antibodies enriched for ADCC activity failed to protect macaques from mucosal challenge [19] . The disappointing results strongly suggest that evidence derived from in vitro assays may not accurately reflect the complexity of human FcgR structure and function and highlight the difficulty in recapitulating similar responses in macaques. Additional reports from at least two groups experimentally readdressed the issue with studies that parsed protection outcomes based on Fc-mediated inhibitory activity. The topical application of nonneutralizing monoclonal antibodies (mAbs) characterized for inhibitory activities, including ADCC, by Moog et al. [20] , failed to protect macaques against vaginal SHIV challenge but showed modest evidence of tempering viremia. Ko et al. [21] engineered an enhanced FcRn-binding variant of bNmAb VRC01 with a three-fold longer serum halflife. The variant, VRC01-LS, showed increased gut mucosal tissue localization and persisted in the rectal mucosa when it was no longer detectable in serum and mediated improved protection against SHIV challenge compared with VRC01 [21] .
Using in vivo infection in the luciferase reporter mouse model, Pietzsch et al. [22] provided convincing evidence for improved efficacy associated with Fc effector function of bNAbs. They correlated the protective ability of bNAbs with engagement of activating FcgRs, but not with in vivo neutralization activity [23 & ]. This study is extremely important for HIV antibody immunotherapy and vaccine strategies designed to elicit protective immunity. Although these and similar outcomes justify the curiosity to determine the contribution of Fc-mediated functions in protection, the abundance of evidence still weighs heavily for neutralization activity as the most predictive metric of protective efficacy in vivo [24] .
Animal models have been extensively used to study the interaction between Fcg receptors and immunoglobulin G (IgG). Despite an overall similarity between human and mouse Fcg receptors, species diversification has resulted in the evolution of a much more complex system in humans, making predictions of biological effect based on extrapolations from mice data a challenging endeavor. Recently, progress in the field of mouse engineering has resulted in the development of a fully humanized Fcg receptor mouse expressing hFcgRI, hFcgRIIA, hFcgRIIB, hFcgRIIIA, and hFcgRIIIB [25, 26] . The closer similarity between humans and macaques compared with humans and mice should make the NHP model much more attractive. Unfortunately, little information is known about the Fcg receptors in nonhuman primates. In addition to FcgR sequences variations, not all macaque FcgR structure and function characteristics are the same as human. For example, the inhibitory macaque FcgRIIB uses an alternative regulatory strategy that could lead to unpredicted complications and misinterpretations of outcomes when testing various human IgG in macaques [27] .
CHARACTERIZING IMMUNITY: B-CELL STUDIES IN RHESUS MACAQUES
In order to gain a better understanding of mucosal and systemic B-cell dynamics in rhesus macaques, Demberg et al. [28] characterized rhesus macaque memory B-cell populations at three mucosal sites. Their results confirm that rectal biopsies adequately report B-cell dynamics in the gut mucosa of macaques and provide new information on the development of B-cell responses associated with protection from infection and control of pathogenesis. A separate report found that rectal explants could be used instead of duodenal tissue for culturing mucosal immunoglobulin A (IgA) from macaques [29] . This awareness can be useful for evaluation of mucosal vaccines.
NONHUMAN PRIMATE MODELS FOR PROTECTION
Neutralizing antibodies (NAbs) raised in macaques following vaccination have been shown to be protective against homologous SHIV challenge [30, 31] , and polyclonal preparations of NAbs derived from infected macaques can block infection and ameliorate disease progression [32, 33] . Several studies established convincing evidence that passive transfer of bNmAbs could prevent infection in macaques against SHIV challenge [18, [34] [35] [36] [37] [38] . However, the neutralization titers in plasma [39] that were needed to confer protection by the few known bNAbs at the time were high and not believed to be a reasonable goal attainable by vaccination. Fortunately, the tide may be turning with the present generation of bNmAbs that target multiple linear and conformational epitopes that are extremely broad and potent in vitro, reviewed by Burton et al. [40] and Kwong and Mascola [41] , and that can prevent mucosal transmission of SHIV in macaques at much lower doses [42] . In fact this year, a notable study using five different potent bNmAbs and a cohort of 60 macaques challenged with two different SHIVs demonstrated that a relatively modest plasma neutralization titer ($1 : 100), which is potentially achievable by vaccination, prevented infection [43 && ]. An interesting caveat to this study was the discovery that in vitro virus neutralization may not be absolutely predictive of in vivo protection. The authors found that an in vitro engineered CD4 binding site (CD4bs) mAb neutralized with very high potency in the TZM-bl cell assay, but it showed no in vivo protection. Pegu et al. [44] also demonstrated a dissimilar protective efficacy between bNmAbs targeting highly conserved epitopes on HIV-1 Env versus a high-affinity anti-CD4bs-directed mAb that had been clearly shown to block HIV-1 entry in vitro. Thus, ongoing vaccine efforts designed to elicit antibodies targeted to specific regions of Env remains a critically important goal. It was also demonstrated this year that the in vitro and in vivo antiviral activities of bNmAbs can be improved further using structure-guided modifications. VRC07-523, an engineered version of VRC01, was enhanced by five to eight-fold in neutralization potency and breadth and protected SHIV-challenged macaques at a five-fold lower concentration [45] . This pioneering study shows innovation for engineering next-generation antibodies for improved therapeutic potential.
USE OF ANIMAL MODELS FOR HIV THERAPIES
The new generation of extremely potent bNmAbs has brought a renewed sense of potential in their use not only as pre-exposure blocking agents (as discussed in the previous section) but also as immunotherapeutics in established infection. In the therapeutic model, a cocktail containing five of the new potent bNmAbs reduced HIV-1 replication for 60 days in humanized mice [46] . This year, the therapeutic potential of cocktails and a single bNmAb (PGT121) was examined in macaques chronically infected with SHIV SF162P3 . Infusion of PGT121 resulted in rapid control of viremia and reduced proviral DNA in peripheral blood and gastrointestinal mucosa [47 && ]. Viral rebound occurred in all animals correlating with decay of the transferred bNmAbs. Detectable provirus DNA in tissues confirmed that virus was not eradicated. Nevertheless, the study is a landmark for preclinical proof of principle. In another study, two potent bNmAbs (3BNC117 and 10-1074) were tested for their ability to block infection and control SHIV-AD8 infection in macaques. Either antibody alone could block virus acquisition and when given together plasma viremia could be transiently suppressed. Virus rebound could also be controlled after a second cycle of therapy [48 && ].
In the humanized mouse model, Halper-Stromberg et al. [49] showed that combinations of viral transcript inducers and bNmAbs can synergize to decrease viral reservoirs in established infection and prevent viral rebound. Moreover, bNmAbs alone were shown to interfere with establishing viral reservoirs by Fc-FcR mechanisms. Balazs et al. [50] recently demonstrated the ability of vectored immunoprophylaxis (VIP) expressing bNmAbs to prevent transmission to humanized mice via intravenous and repeated vaginal exposure. Moreover, mice receiving VIP expressing a modified VRC07 antibody were completely resistant to repetitive intravaginal challenge by a heterosexually T/F HIV strain, suggesting that VIP may be effective in preventing vaginal transmission of HIV between humans. Both animal models strongly suggest a role for antibody immunotherapy alone or in combination with antiretroviral drugs as treatment for chronic infection.
With strict adherence to pre-exposure use, topically applied vaginal microbicide gels have been shown to be a well tolerated and effective intervention to limit HIV transmission [51] . This year, a microbicide gel based on clinically approved integrase inhibitors was tested in pig-tail macaques that can be applied up to 3 h after SHIV exposure [52 & ]. The study addresses the challenge of developing intervention strategies that will enhance user compliance and thereby increase the potential for infection prevention.
An investigation of the contribution of host autologous antibody responses in suppressing host immune escape brings new hope for the potential benefits of monoclonal antibody immunotherapy. Using HIV-1 YU2 -infected humanized mice and panels of isolated antibodies from macaques and humans, Klein et al. [53 & ] showed that antibodies produced during infection that fail to control viremia can synergize with passively administered bNmAbs to prevent the emergence of escape variants.
Finally, in some of the most promising news in many years, a vaccine based on rhesus cytomegalovirus (CMV) that generates very strong and persistent T effector memory partially controlled infection and had the unprecedented outcome of eliminating viral reservoirs in SIV-infected macaques that had been vaccinated with this recombinant virus [54 && ]. These data suggest that some lentiviral reservoirs may be susceptible to the continuous effector memory T-cell-mediated immune surveillance elicited by CMV vectors. This research underscores the importance of using animal models to test concepts that cannot be as easily approached in the clinic.
CONCLUSION
A tractable and affordable animal model for HIV has been a goal for at least 30 years, and important milestones have been accomplished. The past year has heralded the introduction of new animal models and new ways of optimizing established models. NHPs are favored for preclinical protection and therapeutic studies and vaccines, but the recent development of sophisticated mouse models engineered with engrafted parts of the human immune system has added strength to the field. The field is driven by both technology and innovative research, both of which will continue to shape the discoveries of tomorrow. Unprecedented work vividly illustrating HIV-1 virions penetrating mucosal tissue in the FRT. This study provides a direct examination of the mechanism by which HIV enters tissue compartments and goes further to quantify the numbers of infecting virions correlated with depth of tissue penetration. 11.
